Skip to main content

Recombinant Human IL-31 Protein

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-34870

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-34870-500ug
NBP2-34870-1mg
NBP2-34870-10ug
NBP2-34870-100ug

Key Product Details

Source

E. coli

Accession #

Conjugate

Unconjugated

Applications

Bioactivity, SDS-PAGE

Product Specifications

Description

A single non-glycosylated polypeptide chain containing 141 amino acids corresponding to IL-31 Source: E. coli

Uniprot ID: Q6EBC2

Amino Acid Sequence: SHTLPVRLLR PSDDVQKIVE ELQSLSKMLL KDVEEEKGVL VSQNYTLPCL SPDAQPPNNI HSPAIRAYLK TIRQLDNKSV IDEIIEHLDK LIFQDAPETN ISVPTDTHEC KRFILTISQQ FSECMDLALK SLTSGAQQAT T

This lyophilized preparation is stable for 12 months from date of receipt at -20 to -70 degrees C, preferably desiccated. Upon reconstitution, the preparation can be stored for 1 month at 2-8 degrees C under sterile conditions, and for 3 months at -20 degrees C to -70 degrees C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Stock solutions should be aliquoted and stored at < -20 degrees C. Further dilutions should be made in appropriate buffered solutions

Purity

> 97 % pure by SDS-PAGE and HPLC

Endotoxin Level

Less than 1 EU/ug of IL-31 as determined by LAL method.

Predicted Molecular Mass

15.8 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Activity

IL-31 protein is fully biologically active when compared to standard. The specific activity is determined by inducing STAT3 activation using human U-87 MG cells. 5 ng/mL of IL-31 can effectively induce STAT3 activation

Protein / Peptide Type

Recombinant Protein

Scientific Data Images for Recombinant Human IL-31 Protein

SDS-PAGE: Recombinant Human IL-31 Protein [NBP2-34870]

SDS-PAGE: Recombinant Human IL-31 Protein [NBP2-34870]

SDS-Page: Recombinant Human IL-31 Protein [NBP2-34870] - SDS-PAGE with Recombinant human IL-31 protein.

Formulation, Preparation and Storage

NBP2-34870
Formulation Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH7.4.
Preservative No Preservative
Concentration Lyoph
Reconstitution Recommended to centrifuge prior to opening. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/mL. Apportion stock solutions into working aliquots and store at
Format Carrier-Free
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Store at -20 to -70C as supplied. After reconstitution, store at 2 to 8C for 1 month and at -20 to -70C for long term storage. Avoid repeated freeze-thaw cycles.

Background: IL-31

Human IL-31 gene is located on Chr.12. It expresses the IL-31 protein at low levels in the type 2 helper T cells, which exits in testis, bone marrow, skeletal muscle, kidney, colon, thymus, small intestine and trachea. This protein shares several structural and functional characteristics with IL-6, Oncostatin M, LIF, and Cardiotrophin-1. IL-31 signals through IL-31 receptor A and oncostatin M receptor subunits and can activate STAT3 through receptors and maybe involve in skin immunity. It regulated immune responses have been implicated in skin physiology and inflammatory skin diseases. Human IL-31 shares 24 % a.a. sequence identity in the mature protein with mouse IL-31.

Long Name

Interleukin 31

Alternate Names

IL31

Gene Symbol

IL31

UniProt

Additional IL-31 Products

Product Documents for Recombinant Human IL-31 Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Recombinant Human IL-31 Protein

This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...